Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (Cardiovascular Drugs and Therapy, (2020), 34, 3, (357-370), 10.1007/s10557-019-06919-4)

Daniel P. Judge, Arnt V. Kristen, Martha Grogan, Mathew S. Maurer, Rodney H. Falk, Mazen Hanna, Julian Gillmore, Pushkal Garg, Akshay K. Vaishnaw, Jamie Harrop, Christine Powell, Verena Karsten, Xiaoping Zhang, Marianne T. Sweetser, John Vest, Philip N. Hawkins

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (Cardiovascular Drugs and Therapy, (2020), 34, 3, (357-370), 10.1007/s10557-019-06919-4)'. Together they form a unique fingerprint.

Medicine & Life Sciences